Press Releases April 14, 2026 08:00 PM

BOSS Zhipin's Ongoing Share Repurchases Surpass RMB862 Million in 2026

KANZHUN LIMITED intensifies share repurchase program with over RMB862 million spent in 2026 to enhance shareholder value.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, operating under the brand BOSS Zhipin, announced that it has exceeded RMB862 million in share repurchases in 2026, including a recent buyback of 587,254 shares worth RMB27.2 million as part of its ongoing program aimed at returning value to shareholders.

BOSS Zhipin's Ongoing Share Repurchases Surpass RMB862 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has spent over RMB862 million on share repurchases so far in 2026.
  • The company repurchased 587,254 shares worth RMB27.2 million on April 14, 2026.
  • The share buyback program signals strong commitment to enhancing shareholder value amid market activities.

BEIJING, April 15, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.2 million to repurchase 587,254 ordinary shares on April 14. Year-to-date in 2026, the Company has deployed over RMB862 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Market volatility could impact the effectiveness and timing of ongoing share repurchases, affecting capital allocation efficiency.
  • Economic or regulatory changes in China or US markets may influence company performance and investor confidence.
  • Overemphasis on share buybacks might divert funds from other growth opportunities or operational investments.

More from Press Releases

IQM Quantum Computers will change the release date of the interim report for January-September 2026 Oct 5, 2026 Flyte Aviation Launches Under NYSE American Ticker “VJET” Oct 5, 2026 Niu Technologies Provides Third Quarter 2026 Sales Volume Update Oct 5, 2026 FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® Oct 5, 2026 STMicroelectronics announces timing for third quarter 2026 earnings release and conference call Oct 5, 2026